Shanghai Medicilon Inc. announced a private placement of not more than 18,623,864 A shares for gross proceeds of not more than CNY 2,160,000,000 on February 10, 2022. The issue price is not less than 80% of the average price of it's stocks 20 trading days before the first day of the issue period. The transaction will include participation from not more than 35 investors.

The transaction has been approved in the 2nd meeting of the 3rd directorate of the company, and are subject to the approval of the company's shareholders meeting, Shanghai Stock Exchange and the China Securities Regulatory Commission. All securities issued in the transaction have a hold period of 6 months.